2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC). (September 2015) - Shinozaki, E.; Laurent, S.; Gravalos, C.; Benavides, M.; Munoz, F. Longo; Mizuguchi, H.; Wahba, M.; Ychou, M.; Ciardiello, F.; Siena, S.; Yamaguchi, K.; Muro, K.; et al.